TYRP1 and uveal melanoma: Interestingly, 59%, 60%, and 92% of patients with acral, mucosal, and uveal melanoma, respectively, present high expression of TYRP1 (Log2 FPKM ≥ 7, Fig. 1d–f) and could benefit significantly from a T-cell therapy designed to target TYRP1.